论文部分内容阅读
入选病例32例,在应用或停用原降糖药物基础上口服捷诺达24周,结果多项指标较治疗前基础值有所下降,血脂异常有所改变,血清C肽有所升高,低血糖发生率显著减少(P<0.05、P<0.01)。结论捷诺达对血糖控制欠佳2型糖尿病患者具有良好的控制血糖、减轻体重、减少低血糖风险和改善胰岛功能且有较好的安全性、依从性和耐受性。
Selected cases of 32 cases, in the application or discontinuation of the original hypoglycemic drugs based on oral administration of Kenuo Da for 24 weeks, the results of a number of indicators than before treatment baseline values have declined, dyslipidemia has changed, serum C-peptide increased, The incidence of hypoglycemia was significantly reduced (P <0.05, P <0.01). CONCLUSIONS: Jiannuo Da has good control of blood glucose, weight loss, hypoglycemia risk reduction, and improvement of pancreatic islet function in patients with type 2 diabetes who have poor glycemic control and has good safety, compliance and tolerability.